menu
    • menu
    PHARMACOMPASS
    PHARMACOMPASS

    Grow Your Pharma Business Digitally
    X
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    BMS Presents Ph3 Data Showing Sotyktu Superiority in Psoriatic Arthritis

    BUSINESSWIRE

    BMS` Sotyktu Superior In Ph3 POETYK PsA-2 Psoriatic Study

    BUSINESSWIRE

    Five-Year Sotyktu Data Shows Safety In Plaque Psoriasis

    BUSINESSWIRE

    Sotyktu has excelled in 2 psoriatic arthritis trials, BMS says

    FIERCE PHARMA

    Bristol Myers Squibb Presents New Data On Sotyktu Efficacy

    BUSINESSWIRE

    Alumis readies IPO to fund rival drug to Bristol Myers’ Sotyktu

    BIOPHARMADIVE

    Sotyktu 4-Year Data Shows Durable Safety, Response In Psoriasis

    BUSINESSWIRE

    BMS taps Mindy Kaling to join Ted Danson in Sotyktu promos

    FIERCE PHARMA

    Kymera doubles down on protein degraders for immunology

    ENDPTS

    Protagonist Announces Phase 3 ICONIC Studies in Psoriasis Evaluating JNJ-2113

    ACCESSWIRE

    Sotyktu (deucravacitinib) Long-Term Data Demonstrate Durable Efficacy

    BUSINESSWIRE

    BMS’s Sotyktu recommended for NHS use for adult patients with psoriasis

    PHARMAFILE

    BMS says TYK2 inhibitor Sotyktu gains EU approval in psoriasis

    PRESS RELEASE

    BMS debuts first psoriasis drug ad on Grammys, leading chorus of pharma brands

    ENDPTS

    BMS holds on to high Sotyktu hopes, plays down Otelza threat

    FIERCE PHARMA

    BMS Announces Positive CHMP Opinion for Once-Daily Sotyktu for Plaque Psoriasis

    BUSINESSWIRE

    2022 drug approvals: Biopharma delivered 37 new drugs

    FIERCE PHARMA

    Nimbus posts psoriasis data on rival to Bristol Myers` Sotyktu

    FIERCEBIOTECH

    Health Canada Has Approved (Pr)SOTYKTU (deucravacitinib tablets)

    BIOSPACE

    Why Bristol Myers Squibb Stock Bounced Higher Today

    MOTLEY FOOL

    Bristol Myers gets FDA approval for new type of psoriasis drug

    BIOPHARMADIVE

    Bristol Myers Squibb Announces New Sotyktu Long-Term Data

    BUSINESSWIRE

    U.S. Food and Drug Administration Approves Sotyktu

    BUSINESSWIRE

    BMS heads for phase 3 lupus trial for TYK2 inhibitor this year

    FIERCEBIOTECH

    BMS builds the case for psoriasis hopeful as it waits in regulatory limbo

    ENDPTS

    BMS hints its TYK2 inhibitor could take on a form of lupus

    FIERCEBIOTECH

    Bristol`s deucravacitinib not just another JAK drug, exec says

    FIERCEPHARMA

    Amgen`s Otezla Shines Again in Psoriasis

    BIOSPACE

    Bristol Myers up for high-stakes FDA autoimmune drug decision

    FIERCEPHARMA

    BMS’ new JAK inhibitor enters regulatory pathways

    PMLIVE

    Bristol Myers Squibb’s Applications for Deucravacitinib for the Treatment

    BUSINESSWIRE

    Amid JAK debacle, Bristol Myers settles in for FDA`s long review of potential

    ENDPTS

    Analyst puts Amgen`s Otezla, Repatha, biosimilars on notice

    FIERCEPHARMA

    BMS` deucravacitinib flunks midphase IBD trial

    FIERCEBIOTECH

    BMS says deucravacitinib flops mid-stage ulcerative colitis study

    PRESS RELEASE

    FTC zeroes in on potential BMS, Celgene psoriasis overlap

    ENDPTS

    Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.